2018
DOI: 10.1038/s41523-018-0085-3
|View full text |Cite
|
Sign up to set email alerts
|

Androgen receptor expression in normal breast tissue and subsequent breast cancer risk

Abstract: Sex steroid hormone signaling is critical in the development of breast cancers, although the role of the androgen receptor remains unclear. This study evaluated androgen receptor (AR) expression in normal breast tissue as a potential marker of breast cancer risk. We conducted a nested case–control study of women with benign breast disease (BBD) within the Nurses’ Health Studies. Epithelial AR expression was assessed by immunohistochemistry in normal tissue from the BBD biopsy and the percent of positive nuclei… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
17
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 26 publications
(17 citation statements)
references
References 43 publications
(47 reference statements)
0
17
0
Order By: Relevance
“…Details about the study design methods for the NHS and NHSII have been published previously ( 34 ). Eligible women with biopsy-confirmed BBD were placed into 2 substudies—the BBD Incidence study ( 35‐38 ) and/or the BBD BC nested case-control study ( 2 , 3 , 5 , 24 , 30 , 32 , 33 , 39‐41 ). BC diagnosis was confirmed verbally by the participant, via medical record review, or via the cancer registry.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Details about the study design methods for the NHS and NHSII have been published previously ( 34 ). Eligible women with biopsy-confirmed BBD were placed into 2 substudies—the BBD Incidence study ( 35‐38 ) and/or the BBD BC nested case-control study ( 2 , 3 , 5 , 24 , 30 , 32 , 33 , 39‐41 ). BC diagnosis was confirmed verbally by the participant, via medical record review, or via the cancer registry.…”
Section: Methodsmentioning
confidence: 99%
“…Among women diagnosed with BBD, the subsequent BC risk varies with the subtype of BBD in this order: nonproliferative, proliferative without atypia, and proliferative with atypia ( 2–4 ). Researchers continue to identify new biomarkers of risk ( 2 , 3 , 5–8 ) as well as update risk assessment models ( 9–13 ) to improve BC risk prediction. For example, the well-validated Rosner–Colditz model includes age at menarche, age at first birth, age at subsequent births, age at menopause, family history of BC, body mass index (BMI), alcohol intake, and postmenopausal hormone therapy use ( 14 ).…”
mentioning
confidence: 99%
“…In ER positive BC cell, the AR effect appeared to be dual. AR expression is an independent prognostic factor of better outcome in patients with ER-positive BC, but there are also publications that conclude there is no correlation between the presence of these receptors and neoplastic development [35,71,72].…”
Section: Discussionmentioning
confidence: 99%
“…Participants who reported breast cancer were confirmed verbally by the participant, via medical record review, or via the cancer registry. Eligible women with biopsy-confirmed BBD were placed into two sub-studies within the NHS/NHSII—the BBD Incidence study 2831 and/or the BBD breast cancer nested case-control (NCC) study 24,24,26,27,3235 . whole slide images (WSIs) from women in the BBD Incidence study were used in the development phase to engineer the deep-learning networks.…”
Section: Methodsmentioning
confidence: 99%
“…Breast cancer risk factors may be non-modifiable (e.g., genetics, dense breast tissue, and benign breast disease (BBD)) or modifiable (e.g., adiposity and alcohol consumption). Researchers continue to identify new biomarkers of risk 27 as well as update risk assessment models 812 to improve breast cancer risk prediction.…”
Section: Introductionmentioning
confidence: 99%